Illumina's Stock Falls 9 Percent on Grail Acquisition Rumors

NEW YORK – Shares of Illumina have fallen 9 percent from the Wednesday market open and 23 percent from the intraday high on rumors the sequencing giant will acquire liquid biopsy firm Grail.

Following a short rise to an intraday high of $366.01, Illumina's share price fell to $320.70 in afternoon trading on the Nasdaq.